Study Name:
A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC (ALERT-lung study)

Phase:
Phase 2 Clinical Trial

EudraCT number:
2017-002063-17

National Principal Investigator:
Dr. Júlio Oliveira (IPO Porto)

Participating Countries:
Belgium France Germany Ireland Italy, The Netherlands, Portugal, Slovenia, Spain, Switzerland.

Sites in Portugal:
IPO Porto

Sponsor:
European Thoracic Oncology Platform (ETOP)

Status:
Submission phase